July 10, 2012
Krebs-Gedächtnis dank trifunktionaler Antikörper
Read more

Key information on Triomab®
undefinedTriomab® backgrounder

Video, interviews, pictures and background information by Fresenius
undefinedMedia information


Removab® is the most advanced representative of TRION’s unique family of trifunctional Triomab® antibodies. It received EU market approval for the treatment of malignant ascites in April 2009 and is the first bispecific, trifunctional antibody on the market worldwide.

Removab® was invented by TRION Pharma and is manufactured at TRION’s GMP-facilities in Munich, Germany. 
Removab® is marketed by Fresenius Biotech.

If you are a patient or physician and want to learn more about clinical applications and access to Removab®, please contact Fresenius Biotech directly by e-mail: Med.Info(at)Fresenius-Biotech.com

If you want to learn more about Removab®’s design and its therapeutic mode of action, please browse the undefinedTriomab® section of this website orundefined information about malignant ascites. Further background and download materials are available for media professionals in our undefinedNews & Events section.